Latest news with #HIMS
Yahoo
2 days ago
- Business
- Yahoo
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
Hims & Hers Health, Inc. HIMS announced its agreement to acquire ZAVA, a digital health platform in Europe. The deal, which marks a significant step toward its global expansion, will likely expand HIMS' footprint in the U.K. and will officially launch the company into Germany, France and Ireland, with more markets anticipated soon. The acquisition is expected to close in the second half of 2025, and the deal is expected to be accretive by 2026. Hims & Hers is also planning to introduce a new, personalized dimension of digital health in Europe. Through this, the company aims to provide individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a localized experience, this expansion is also expected to include access to British, German and French healthcare providers in local languages. Hims & Hers expects to share more about the offerings and their rollout in the coming months. The latest acquisition and subsequent expansion in the European markets are expected to significantly solidify HIMS' international footprint. Following the announcement, shares of the company lost nearly 3.6% till yesterday's closing. Historically, the company has gained synergies from its various strategic buyouts. Although the latest deal is likely to be beneficial for HIMS' top-line growth going forward, the stock declined overall. Hims & Hers currently has a market capitalization of $12.25 billion. It has an earnings yield of 1.3%, favorable than the industry's negative yield. In the last reported quarter, HIMS delivered an earnings surprise of 66.7%. Hims & Hers aims to establish its own branded presence, leveraging the ZAVA platform in each of the European markets in the coming quarters and strengthening its digital health offerings on a global scale. It is worth mentioning that ZAVA, which currently serves more than 1.3 million active customers, has an in-house medical team that delivered nearly 2.3 million consultations in 2024 across the U.K., Germany, France and Ireland. Hims & Hers' management expects to leverage ZAVA's established European presence to transform access to care for people across Europe battling widespread, often silent chronic conditions like obesity and depression. Per a report by Grand View Research, the global digital health market was estimated at $288.55 billion in 2024 and is anticipated to witness a CAGR of 22.2% between 2025 and 2030. Factors like the rising incidence of chronic conditions fueling the demand for remote monitoring and management solutions, and technological advancements are likely to drive the market. Given the market potential, the latest buyout is expected to be a significant milestone for Hims & Hers and boost its business globally. In February, Hims & Hers acquired a U.S.-based peptide facility based in California. The buyout will likely enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options. The same month, Hims & Hers acquired an at-home lab testing facility, Sigmund NJ LLC, which is marketed as Trybe Labs. The buyout will likely enable HIMS to support at-home blood draws and more comprehensive whole-body testing. The acquisition is also expected to broaden the company's ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into new clinical categories, including low testosterone, perimenopausal and menopausal support. Shares of the company have surged 154.1% in the past year compared with the industry's 33.8% rise and the S&P 500's gain of 11.4%. Image Source: Zacks Investment Research Currently, HIMS carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are HealthEquity, Inc. HQY, Cencora, Inc. COR and Integer Holdings Corporation ITGR. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 20.3%. HQY's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 12.4%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. HealthEquity's shares have gained 34.9% against the industry's 21.7% decline in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora has rallied 25.3% against the industry's 21.7% decline in the past year. Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings' shares have lost 0.7% compared with the industry's 13.2% plunge in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
2 days ago
- General
- Time of India
Govt starts process to hire VCs for 13 varsities
Bhubaneswar: Govt on Wednesday invited applications for the appointment of vice-chancellors of 13 state universities. The universities were facing difficulty in making important policy decisions and conducting faculty recruitment due to the lack of permanent VCs and faculty members, which the TOI had highlighted in a series of reports. The higher education department has invited applications from eligible applicants for VCs of 13 state public universities — Utkal University and Rama Devi Women's University, Bhubaneswar, Ravenshaw University and Madhusudan Law University, Cuttack, Maharaja Sriram Chandra Bhanjadeo University, Baripada, Gangadhar Meher University, Sambalpur, Fakir Mohan University, Balasore, Khallikote Unitary University, Berhampur, Shree Jagannath Sanskrit University, Puri, Rajendra University in Balangir, Dharanidhar University in Keonjhar, Vikram Dev University, Jeypore, and Maa Manikeshwari University, Kalahandi. VC appointment is necessary to start the process for the recruitment of faculty members. Teaching and research work have been affected due to the lack of faculty members. Candidates must submit their applications by July 5. Applications are invited from eligible applicants below 66 years of age on Dec 1, 2025, for the VC posts. "Applicants intending to apply for more than one university must submit a single application clearly indicating their order of preference, with the most preferred university listed first," read the official notification. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo The notification stated the order of preference must also be clearly specified in the Higher Education Information Management System (HIMS) module. Shortlisted candidates will be called for an interview before a three-member selection committee. The venue and schedule will be communicated in due course, higher education secretary Aravind Agrawal said in the notification. Official sources said the interview dates will be fixed for different universities on different dates, and applicants are required to attend the interview for each university separately. The 2020 amendment Act said all teachers of a university would be appointed through Odisha Public Service Commission (OPSC). However, the Odisha Universities Amendment Act, 2024, clearly states a selection committee will be formed to recruit faculty members by following UGC guidelines. The committee will be chaired by the vice-chancellor of the university or his/her nominee. The faculty selection committee will include an academic not below the rank of a professor nominated by the chancellor. It will have three subject experts selected by the VC from a panel of names recommended by the syndicate. Other members will include the dean of faculty or head of the department, along with an academic from ST/SC/OBC/women/minority/PWD as per the candidate present, to be nominated by the VC.
Yahoo
3 days ago
- Business
- Yahoo
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus.
Yahoo
3 days ago
- Business
- Yahoo
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Hims & Hers, Joby Aviation, Pinterest: Trending Tickers
Hims & Hers Health (HIMS) will be acquiring European telehealth platform Zava in an all-cash deal. Joby Aviation (JOBY) is exploring an agreement to sell up to 200 of its air taxis to a Saudi Arabian investor. Also watch Yahoo Finance's interview with Joby Aviation CEO JoeBen Bevirt from October 2024. JPMorgan analysts upgraded Pinterest (PINS) shares to Overweight. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. Sign in to access your portfolio
